Ethanol
| Evidence Level: L4 | Predicted Indications: 2 |
Table of Contents
- Ethanol
- Pharmacist Assessment Report
- Ethanol: From an Unspecified Original Indication to Migraine Disorder
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Ethanol: From an Unspecified Original Indication to Migraine Disorder
One-Sentence Summary
Ethanol is registered in Australia, but the data compiled for this report contain no approved indication text for it. The TxGNN model predicts it may be effective for migraine disorder, but there are no registered clinical trials and the retrieved literature largely describes ethanol as a migraine trigger, not a treatment. Overall this is a model-only signal that the available evidence does not support.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no approved indication text in the registration data) |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 0.9929 |
| Evidence Level | L4 (preclinical and mechanistic literature only, and it points to a pro-migraine effect) |
| Australia Market Status | Listed on the PBS Schedule (2 of 2 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 2 (valid: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for ethanol. Known pharmacology includes GABA-A positive modulation and central nervous system depression, but no therapeutic link to migraine has been established.
The data compiled for this report argue against the prediction. Alcohol is a recognised migraine trigger. Preclinical work shows ethanol is metabolised to acetaldehyde, which acts through CGRP receptor and TRPA1 signalling in Schwann cells to produce periorbital allodynia in mice. Genetic studies link ADH2 genotype and GABA receptor variants to migraine risk, but they do not show a treatment effect.
The high score (0.9929) most likely reflects network proximity to migraine-related pathways (GABA, CGRP, TRPA1, KATP channels) and not a therapeutic effect. Therapeutic repurposing is not supported.
Clinical Trial Evidence
Currently no related clinical trials registered for migraine disorder.
Literature Evidence
No randomised trials of ethanol in migraine were retrieved. The most relevant items are below, in priority order.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36373782 | 2022 | Review | Headache | Reviews the complex relationship between alcohol and migraine (no abstract available) |
| 35063053 | 2022 | Cohort | Aerosp Med Hum Perform | Migraine outcomes in military pilots and flight surgeons; considers modifiable aggravating factors |
| 19486361 | 2010 | Genetic association | Headache | Investigates ADH2 genotype (ethanol metabolism) and migraine risk |
| 37101198 | 2023 | Preclinical | J Biomed Sci | Acetaldehyde acts via CGRP receptor and TRPA1 in Schwann cells to mediate ethanol-evoked allodynia in mice |
| 40785517 | 2025 | Preclinical | Cephalalgia | KATP channel opening activates meningeal nociceptors; relevant to migraine origin |
| 29299688 | 2018 | Genetic association | J Neural Transm | GABA receptor gene polymorphisms (GABRA4, GABRE, GABRQ) and migraine risk |
| 28699326 | 2017 | Genetic association | Headache | GABA receptor rho gene polymorphisms and migraine risk |
| 31792366 | 2020 | Genetic association | Pharmacogenomics J | NOS3 rs2070744 and migraine risk |
Several other retrieved papers are unrelated to ethanol as a treatment (for example sumatriptan pharmacokinetics, carisbamate, and formulation studies using ethanol as a solvent).
Australia Market Information
The registration data list 2 valid single-ingredient entries. Product names, dosage forms and approved indication text are not available for either entry.
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 128R | Not available | Not available | Not available |
| ARTG 127Q | Not available | Not available | Not available |
Safety Considerations
- Drug Interactions: The interaction screen returned 100 interactions. The first 20 reviewed include one Major interaction with eluxadoline. Most of the remainder are Moderate, including:
- Antidiabetic agents (acarbose, acetohexamide, chlorpropamide, albiglutide, dulaglutide, alogliptin, canagliflozin, dapagliflozin, empagliflozin)
- Anticholinergics (atropine, clidinium, dicyclomine)
- Others (acetylsalicylic acid, bupropion, dronabinol, dexfenfluramine, diethylpropion)
Minor interactions include doxycycline and cimetidine.
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on model score alone. The literature indicates ethanol triggers migraine, with no clinical trials and no therapeutic evidence. Ethanol is a cause of sleep disruption and neuropathy in the retrieved studies.
To proceed, the following is needed:
- Approved indication text and product details for the two ARTG entries
- Detailed mechanism of action data
- TGA Product Information warnings and contraindications
- Controlled clinical evidence of benefit in migraine, which is currently absent and contradicted by existing data
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.